What the 7-OH Scheduling Means for Retailers — and the Comment Window That's Still Open

A brief for wholesale buyers, distributors, and retail operators. This is informational, not legal advice, and contains no health or efficacy claims. Products discussed are for adults 21+.

On July 1, 2026 the DEA announced its intent to temporarily place 7-hydroxymitragynine (7-OH) above a specified threshold into Schedule I, alongside related substances (mitragynine pseudoindoxyl, MGM-15, MGM-16). The formal notices published in the Federal Register on July 6 (2026-13580 / 2026-13581), opening a public comment window that closes July 31, 2026 under docket HHS-OASH-2026-0232.

If you carry, distribute, or are evaluating this category, two things are true at once: you need a compliance plan, and the rule is not yet final. This brief covers both. For the full documented record behind it, see the 7-OH ban report on Wholesome Fraction.

---

What this actually does to your shelf

Temporary scheduling under 21 U.S.C. § 811(h) is emergency authority. Key features every operator should understand:

• It runs on a compressed timeline — 30 days' notice, then an order that lasts one year, extendable six months while permanent rulemaking proceeds.
• The statute states an emergency order "is not subject to judicial review." You cannot litigate your way out of the temporary order on the merits. The realistic check is the political and public-comment channel — which is exactly why the July 31 window matters.
• The action targets concentrated/above-threshold 7-OH, not natural leaf kratom and not mitragynine. The threshold in the notice is 0.050% dry weight in botanicals, or ≥0.050% / ≥1.00 mg in processed extracts, concentrates, edibles, and pills made via synthetic methods.

Practical read: this is aimed squarely at high-potency concentrate SKUs and can remove above-threshold product from lawful commerce during the control period. Plan inventory and sourcing accordingly, and document your compliance posture now.

---

The context buyers should have: this is an intra-industry fight

One point worth keeping in view for any procurement or category decision: the push to schedule 7-OH has been driven substantially by the natural-leaf kratom industry, which treats concentrated 7-OH as a competitive threat — trade coverage has framed the DEA action as a win for the mainstream leaf-kratom industry. This is, in large part, one segment of the kratom market moving against another, not a neutral public-health groundswell. (The detailed public-record money trail behind that is documented separately; this brief stays on what it means for your shelf and the open comment window.)

---

The instrument critique — the argument that holds up

Do not let this get framed as "7-OH is safe versus 7-OH is dangerous." That is not the defensible position and it is not ours. Concentrated 7-OH is not the 2016 natural leaf, and no serious filing should pretend it is.

The substantive objection is about the choice of instrument. When a category raises real questions, there is a well-established regulatory toolkit short of emergency criminalization:

• Kratom Consumer Protection Acts — roughly two dozen states already impose age gates, concentration caps (commonly capping 7-OH as a share of total alkaloids), contaminant testing, and labeling/COA requirements.
• The Thailand framework, which restricts added and concentrated 7-OH specifically while regulating the leaf — a working model of product-standard control without Schedule I.
• GMP, mandatory testing, and honest labeling as baseline market-entry conditions.

Each of these directly addresses the stated concern about high-potency product. Emergency Schedule I — the fastest, least-reviewable, most disruptive tool available — bypasses all of them. That is a legitimate procedural objection you can raise on the record without endorsing any product or making any health claim.

---

The precedent worth knowing

In 2016, the DEA issued a nearly identical emergency notice covering mitragynine and 7-OH. It was withdrawn in October 2016 after a 142,000+ signature petition, a bipartisan 50+ member House letter (Reps. Mark Pocan and Matt Salmon), and a separate letter from nine Senators calling emergency scheduling of a natural substance "unprecedented." The DEA reopened a normal comment process and the ban never took effect.

The honest distinction: 2016 targeted the whole leaf; 2026 targets the concentrate. The precedent does not prove the two targets are equivalent. What it does prove is that the comment channel is the mechanism that has actually stopped this before — and it is open again until July 31.

---

The industry call: file substantive comments before July 31

Retailers, distributors, and manufacturers carry more weight on the record than individual consumers, because you can speak to real market and compliance impact. A strong industry comment is specific and evidence-based, not a form letter (identical letters are counted once).

File at regulations.gov under docket HHS-OASH-2026-0232, before July 31, 2026. Effective comments:

1. 1. Identify your standing — the nature and size of your operation, and your lawful, 21+ compliance practices.
2. 2. Argue the instrument, not the molecule — object to emergency Schedule I as disproportionate given available, proven alternatives (state KCPAs, the Thailand concentrate-restriction model, GMP/testing/labeling).
3. 3. Speak to real-world impact — documented compliance costs, lawful-market displacement, and the diversion-to-unregulated-channels risk that criminalization can create.
4. 4. Request the full process — ask the agencies to complete the standard scientific analysis with public input before permanent action, the off-ramp taken in 2016.
5. 5. Keep it clean — no health, medical, or efficacy claims; factual, professional, and sourced.

The permanent rulemaking that follows is subject to ordinary review, so a well-built record now also positions the category for that later stage.

---

Bottom line for buyers

Treat above-threshold 7-OH as compliance-sensitive today and plan sourcing and inventory around the control-period timeline. At the same time, recognize that the rule is not final and the one channel that has historically checked this kind of action is open until July 31, 2026. File a substantive comment on docket HHS-OASH-2026-0232, argue the instrument, and point your partners to the deadline.

For the complete documented record — FEC filings, court records, the statutory timeline, and every source — read the full 7-OH ban report on Wholesome Fraction.

Trade audience, 21+. Informational only; not legal advice. These statements have not been evaluated by the FDA and are not health or efficacy claims.